These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28777298)

  • 1. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
    Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE
    Ganguly R; Sahu S; Ohanyan V; Haney R; Chavez RJ; Shah S; Yalamanchili S; Raman P
    Sci Rep; 2017 Mar; 7():45279. PubMed ID: 28345659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of betulinic acid on early atherosclerosis in diabetic apolipoprotein-E gene knockout mice.
    Yoon JJ; Lee YJ; Han BH; Choi ES; Kho MC; Park JH; Ahn YM; Kim HY; Kang DG; Lee HS
    Eur J Pharmacol; 2017 Feb; 796():224-232. PubMed ID: 27894808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
    Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
    Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes.
    Hanssen NM; Brouwers O; Gijbels MJ; Wouters K; Wijnands E; Cleutjens JP; De Mey JG; Miyata T; Biessen EA; Stehouwer CD; Schalkwijk CG
    Cardiovasc Res; 2014 Oct; 104(1):160-70. PubMed ID: 25139743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-27 Prevents Atherosclerosis by Suppressing Lipoprotein Lipase-Induced Lipid Accumulation and Inflammatory Response in Apolipoprotein E Knockout Mice.
    Xie W; Li L; Zhang M; Cheng HP; Gong D; Lv YC; Yao F; He PP; Ouyang XP; Lan G; Liu D; Zhao ZW; Tan YL; Zheng XL; Yin WD; Tang CK
    PLoS One; 2016; 11(6):e0157085. PubMed ID: 27257686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ.
    Sanada J; Kimura T; Shimoda M; Iwamoto Y; Iwamoto H; Dan K; Fushimi Y; Katakura Y; Nogami Y; Shirakiya Y; Yamasaki Y; Ikeda T; Nakanishi S; Mune T; Kaku K; Kaneto H
    Cardiovasc Diabetol; 2024 Mar; 23(1):105. PubMed ID: 38504316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
    Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Dimethyl Fumarate on Atherosclerosis in the Apolipoprotein E-Deficient Mouse Model with Streptozotocin-Induced Hyperglycemia Mediated By the Nuclear Factor Erythroid 2-Related Factor 2/Antioxidant Response Element (Nrf2/ARE) Signaling Pathway.
    Luo M; Sun Q; Zhao H; Tao J; Yan D
    Med Sci Monit; 2019 Oct; 25():7966-7975. PubMed ID: 31645538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.
    Kimura T; Obata A; Shimoda M; Okauchi S; Kanda-Kimura Y; Nogami Y; Moriuchi S; Hirukawa H; Kohara K; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2018 Oct; 20(10):2442-2457. PubMed ID: 29873444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE
    Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z
    Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929
    [No Abstract]   [Full Text] [Related]  

  • 13. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Lewis P; Stefanovic N; Pete J; Calkin AC; Giunti S; Thallas-Bonke V; Jandeleit-Dahm KA; Allen TJ; Kola I; Cooper ME; de Haan JB
    Circulation; 2007 Apr; 115(16):2178-87. PubMed ID: 17420349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-atherosclerosis and hyperlipidemia effects of herbal mixture, Artemisia iwayomogi Kitamura and Curcuma longa Linne, in apolipoprotein E-deficient mice.
    Shin HS; Han JM; Kim HG; Choi MK; Son CG; Yoo HR; Jo HK; Seol IC
    J Ethnopharmacol; 2014 Apr; 153(1):142-50. PubMed ID: 24508858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hawthorn (Crataegus pinnatifida Bunge) leave flavonoids attenuate atherosclerosis development in apoE knock-out mice.
    Dong P; Pan L; Zhang X; Zhang W; Wang X; Jiang M; Chen Y; Duan Y; Wu H; Xu Y; Zhang P; Zhu Y
    J Ethnopharmacol; 2017 Feb; 198():479-488. PubMed ID: 28119096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
    Tikellis C; Jandeleit-Dahm KA; Sheehy K; Murphy A; Chin-Dusting J; Kling D; Sebokova E; Cooper ME; Mizrahi J; Woollard KJ
    Atherosclerosis; 2008 Jul; 199(1):55-64. PubMed ID: 18093596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice.
    Shemesh S; Kamari Y; Shaish A; Olteanu S; Kandel-Kfir M; Almog T; Grosskopf I; Apte RN; Harats D
    Atherosclerosis; 2012 Jun; 222(2):329-36. PubMed ID: 22236482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.
    Qiang S; Nakatsu Y; Seno Y; Fujishiro M; Sakoda H; Kushiyama A; Mori K; Matsunaga Y; Yamamotoya T; Kamata H; Asano T
    Diabetol Metab Syndr; 2015; 7():104. PubMed ID: 26594248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
    Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
    Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrf2 in bone marrow-derived cells positively contributes to the advanced stage of atherosclerotic plaque formation.
    Harada N; Ito K; Hosoya T; Mimura J; Maruyama A; Noguchi N; Yagami K; Morito N; Takahashi S; Maher JM; Yamamoto M; Itoh K
    Free Radic Biol Med; 2012 Dec; 53(12):2256-62. PubMed ID: 23051009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.